Louvain-La-Neuve, Belgium, Dimitrovgrad, Russian Federation, October 19, 2016 - IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer, announces the delivery and installation of the Cyclone® 230 for a new proton therapy center in Dimitrovgrad (Ulyanovsky region, Russia). The center will be a part of the Federal High-Tech Center of Medical Radiology of the Federal Medico-Biological Agency of Russia (FMBA).

IBA will equip the center with the Proteus®PLUS* four-treatment room configuration, which provides the best in class treatment with Image Guided Intensity Modulated Proton Therapy (IMPT).

The installation of the facility started in August 2016. The acceptance of the first treatment room is planned for the end of 2017. The proton therapy center in Dimitrovgrad will be IBA’s first in the Russian Federation and is expected to treat up to 1,200 patients per year.
The Head of FMBA, Mr. Vladimir Uiba, Governor of Ulaynovsky region, Mr. Sergey Morozov, and local media were in attendance at this important event for IBA, FMBA and Russia. Representing IBA was Vice-President and the Director of the IBA’s Representative office in Russia, CIS Mr. Kirill Makarenko, as well as the wider IBA site team.

Mr. Vladimir Uiba, Head of FMBA of Russia, emphasized: ''This is a historical event not only for the Ulyanovsky region but also for the whole country. The proton therapy technology produced by IBA is ground-breaking and highly-praised also by the scientists and specialists in the Joint Institute of Nuclear Research in Dubna. Proton therapy is a unique method for cancer treatment and it is at the cutting edge of innovation in oncology."

Kirill Makarenko, Vice-President of IBA and Director of the IBA’s Representative office in Russia, commented on this achievement and its importance for the Russian region: “There are around 500,000 new cancer cases diagnosed in Russia every year and many of them could be treated with proton therapy. The center in Dimitrovgrad will be the first of its kind available to cancer patients from the Ulyanovsky region and the whole Privolzhsky Federal District.”
* Proteus®PLUS is the brand name of a Proteus®235 configuration.

Watch a video about this event on the Russia TV Channel: https://www.youtube.com/watch?v=T0XrbeO8FuM


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Rad Oncology Homepage